Skip to main content

Recombinant Human IL-1 RAcP/IL-1R3 ST2/IL-33R Fc Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 11268-CP

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
11268-CP-050

Key Product Details

Source

CHO

Accession #

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived human IL-1 RAcP/IL-1 R3 protein
Human IL-1 RAcP/IL-1 R3
(Ser21-Glu359)
Accession # Q9NPH3.2
Human ST2/IL-33R
(Lys19-Ser328)
Accession # Q01638.4
IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ser21

Predicted Molecular Mass

102 kDa

SDS-PAGE

130-144 kDa, under reducing conditons.

Activity

Measured by its binding ability in a functional ELISA.
When Recombinant Human IL-1 RAcP/IL-1 R3 ST2/IL-33R Fc Chimera (Catalog # 11268-CP) is immobilized at 1 µg/mL (100 µL/well), Recombinant Human IL-33 (Catalog # 3625-IL) binds with an ED50 of 2.50-25.0 ng/mL.

Scientific Data Images for Recombinant Human IL-1 RAcP/IL-1R3 ST2/IL-33R Fc Protein, CF

Recombinant Human IL-1 RAcP/IL-1R3 ST2/IL-33R Fc Chimera Protein Binding Activity.

When Recombinant Human IL-1 RAcP/IL-1R3 ST2/IL-33R Fc Chimera Protein (Catalog # 11268-CP) is immobilized at 1 µg/mL (100 µL/well), Recombinant Human IL‑33 (3625-IL) binds with an ED50 of 2.50-25.0 ng/mL.

Recombinant Human IL-1 RAcP/IL-1 R3 ST2/IL-33R Fc Chimera Protein SDS-PAGE.

2 μg/lane of Recombinant Human IL-1 RAcP/IL-1 R3 ST2/IL-33R Fc Chimera Protein (Catalog # 11268-CP) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 130-144 kDa.

Formulation, Preparation and Storage

11268-CP
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IL-1 RAcP/IL-1 R3

Serum stimulation-2 (ST2), also known as IL-1RL1, heterodimerizes with IL1-R3, also referred to as IL-1RAP, IL-1R3, or C3orf13, after binding IL-33 (1). The 556 aa human ST2 contains an 18 aa signal peptide sequence, 310 amino acid (aa) extracellular domain, 21 aa transmembrane region, and 207 cytoplasmic domain. ST2 contains three extracellular IgG domains and an intracellular TIR domain. The 570 aa human 1L-1R3 contains a 20 aa signal peptide sequence, 347 aa extracellular domain, 21 aa transmembrane region, and 182 cytoplasmic domain. Differential promoter binding of ST2 generates two main splice variants, a membrane-bound receptor (ST2) expressed on cardiomyocytes and a variety of immune cells that promotes NF-kappa B signaling and a soluble form (sST2) that prevents its signaling, which can be produced spontaneously by lung, kidney, heart, and small intestine cells or by activated mast cells and TH2 cells (2). Two less well understood ST2 splice variants include ST2V, expressed highly in gastrointestinal organs (3), and ST2LV, secreted by eye, heart, lung, and liver tissues (4). Within the ECD, human ST2 shares 68% and 64% aa sequence identity with mouse and rat ST2, and human 1L-1R3 has 86% and 94% aa sequence identity with mouse and rat IL-1R3. After ST2 binds to IL-33 and heterodimerization with IL-1R3, the TIR domain can be activated by MyD88 and IL-1R-associated kinase activation to activate MAPK or NF-kappa B pathways (1). While the mechanisms/signals are unclear, TRAF6 is required for NF-kappa B but not for MAPK activation (5). ST2 participates in a variety of disease implications, especially with its association with immune cells. For example, IL-33 signaling through ST2 is involved with lung diseases in allergic asthma (6), both participating in inflammation but also in its maintenance (7). With skin diseases, upregulation of ST2 and IL-33 has been observed with atopic dermatitis (8), psoriasis (9), and vitiligo (10).

References

  1. Chackerian, A.A. et al. (2007) J. Immunol. 179:2551.
  2. Bergers, G. et al. (1994) EMBO. J. 13:1176.
  3. Tago, K. et al. (2001) 285:1377.
  4. Hiroyuki, I. et al. (2004) Biochim. Biophys. Acta. 24:1.
  5. Funakoshi-Tago, M. et al. (2008) Cell. Signal. 20:1679.
  6. Kearley, J. et al. (2009) Am. J. Respir. Crit. Care. Med. 179:772.
  7. Coyle, A.J. et al. (1990) J. Exp. Med. 190:895.
  8. Imai, Y. et al. (2013) PNANS. 110:13921.
  9. Hueber, A.J. et al. (2011) Eur. J. Immunol. 41:2229.
  10. Li, P. et al. (2015) Clin. Exp. Dermatol. 40:163.

Long Name

Interleukin 1 Receptor Accessory Protein

Alternate Names

IL-1 R3, IL-1RAcP, IL1RAcP, IL1RAP

Entrez Gene IDs

3556 (Human); 16180 (Mouse)

Gene Symbol

IL1RAP

Additional IL-1 RAcP/IL-1 R3 Products

Product Documents for Recombinant Human IL-1 RAcP/IL-1R3 ST2/IL-33R Fc Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human IL-1 RAcP/IL-1R3 ST2/IL-33R Fc Protein, CF

For research use only

Loading...
Loading...
Loading...